Clinical Trial Update: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) [Phase 3]

View source ↗

Summary

Phase 3 PALOMA-3 trial evaluated palbociclib plus fulvestrant in HR+ HER2-negative metastatic breast cancer after endocrine failure; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-05-23